J. J. Halperin, MD,
E. D. Shapiro, MD,
E. Logigian, MD,
A. L. Belman, MD,
L. Dotevall, MD,
G. P. Wormser, MD,
L. Krupp, MD,
G. Gronseth, MD and
C. T. Bever, Jr, MD
From the Department of Neurosciences (J.J.H.), Overlook Hospital, NYU School of Medicine, Summit, NJ; Departments of Pediatrics and Epidemiology and Public Health (E.D.S.), Yale University School of Medicine, New Haven, CT; Department of Neurology (E.L.), University of Rochester School of Medicine and Dentistry, NY; Department of Neurology (A.L.B., L.K.), SUNY, Stony Brook, NY; Department of Infectious Diseases (L.D.), Sahlgrenska University Hospital, Gothenburg, Sweden; Division of Infectious Diseases (G.P.W.), Department of Medicine, New York Medical College, Valhalla; Department of Neurology (G.G.), University of Kansas Medical Center; and Research Service, VAMHCS, and the Department of Neurology (C.T.B.), University of Maryland School of Medicine.
Figure Relative efficacy of doxycycline vs parenteral treatment
Relative efficacy of doxycycline vs parenteral treatment (ratio of response rate to doxycycline to response rate to parenteral penicillin or ceftriaxone; RR of 1.0 indicating identical response rates with the agents being compared) in eight studies, and in aggregate. Responses in most studies were judged clinically; in study 6, CSF criteria were used as well. For summed data, RR is 0.986 (95% CIs 0.948 to 1.025). Additional analyses of doxycycline vs parenteral penicillin or ceftriaxone individually and of parenteral penicillin vs ceftriaxone similarly showed no significant differences. Key to studies: #127; #219; #315; #434; #514; #620; #733; #835.